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Abstract: 
Rapid mixing of substrate-free ferric cytochrome P450BM3–F87G with m-chloroperoxybenzoic acid (mCPBA) 
resulted in the sequential formation of two high-valent intermediates. The first was spectrally similar to 
compound I species reported previously for P450CAM and CYP 119 using mCPBA as an oxidant, and it featured 
a low intensity Soret absorption band characterized by shoulder at 370 nm. This is the first direct observation of 
a P450 compound I intermediate in a type II P450 enzyme. The second intermediate, which was much more 
stable at pH values below 7.0, was characterized by an intense Soret absorption peak at 406 nm, similar to that 
seen with P450CAM [T. Spolitak, J.H. Dawson, D.P. Ballou, J. Biol. Chem. 280 (2005) 20300–20309]. Double 
mixing experiments in which NADPH was added to the transient 406 nm-absorbing intermediate resulted in 
rapid regeneration of the resting ferric state, with the flavins of the flavoprotein domain in their reduced state. 
EPR results were consistent with this stable intermediate species being a cytochrome c peroxidase compound 
ES-like species containing a protein-based radical, likely localized on a nearby Trp or Tyr residue in the active 
site. Iodosobenzene, peracetic acid, and sodium m-periodate also generated the intermediate at 406 nm, but not 
the 370 nm intermediate, indicating a probable kinetic barrier to accumulating compound I in reactions with 
these oxidants. The P450 ES intermediate has not been previously reported using iodosobenzene or m-periodate 
as the oxygen donor. 
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Article: 
 
1. INTRODUCTION 
 
There has been a great deal of interest in identifying reactive intermediates in the catalytic cycle of cytochrome 
P450 for the past quarter of a century. The application of new technologies to the direct observation of certain 
chemical species has contributed considerably to the characterization of these intermediates. For example, 
cryogenic methods have been used to study the properties of ferrous-oxy complexes of a variety of different 
P450 isoforms [1–3]. These low temperature studies have also facilitated the production and stabilization of 
several intermediates in the proposed P450 catalytic cycle beyond the second electron transfer, including a 
ferric-peroxo complex [4,5]. However, as information has accumulated, more questions have arisen as to the 
precise chemical nature of the ultimate hydroxylating species, as well as whether there is only one such oxidant 
in P450 catalysis. The consensus is that a ferryl [Fe
IV
=O] porphyrin radical species, similar to the more stable 
compound I (Cpd I) from various peroxidases, is involved in the majority of oxidative reactions carried out 
 
by P450 enzymes (Scheme 1). While Cpd I has only been directly observed in two bacterial P450 enzymes [6–
8], the argument is made that this species is probably universal among P450s. It is interesting that the only 
stopped-flow experiments in which clearly identifiable Cpd I could be directly observed required the use of the 
oxidant m-chloroperoxybenzoic acid (mCPBA) as the oxygen atom donor. No other oxidant has been 
successfully employed to directly form significant quantities of this species in solution. Stopped-flow studies of 
the reactions of rabbit liver microsomal P450s with peroxides, peracids [9], and iodosobenzene [10] have also 
been reported; however, no transient Cpd I-like intermediates were observed. 
 
Schünemann et al., using EPR and Mössbauer techniques and peracetic acid as an oxygen donor, could not 
detect any Cpd I with P450CAM, but they did identify a species containing a tyrosine radical and a Fe
IV
=O 
[11,12]. This type of species, often called Compound ES (Cpd ES) [8], is well known in cytochrome c 
peroxidase (CcP). In CcP, Cpd ES has been shown by a variety of techniques to contain an Fe
IV
=O prosthetic 
heme coupled to an active site Trp radical cation [13]. Recent reports on P450 [7,8] seemed to indicate that Cpd 
I was only observable when mCPBA was the oxidant, and that only Cpd ES was observable when peracetic acid 
was used [11,12,14]. Spolitak et al. recently addressed this discrepancy using detailed stopped-flow 
spectroscopic analysis of the reaction between substrate-free ferric P450CAM and either peracetic acid or 
mCPBA at several different pH values [8]. They concluded that a considerable fraction of the P450CAM formed 
a CcP Cpd ES-like intermediate below pH 7.0, whereas above pH 7.0, some Cpd I could be observed, albeit 
transiently. Cpd I decayed partially to a Cpd ES-like species as well as to heme degradation products due to 
further reactions of the higher oxidation states of the heme with the excess per- acid. Thus, for P450CAM, the pH, 
as well as the oxidant, determined how much of each form of the oxidized intermediate was observed. Related 
intermediates containing oxidized amino acid residues have also been observed in a variety of heme containing 
enzymes including myoglobin and catalase-peroxidase [15,16]. 
 
Cytochrome P450BM3 has been heralded as a bacterial model enzyme for microsomal P450 enzymes because it 
contains both a flavin-containing redox partner (NADPH cytochrome P450 reductase) and the heme P450 
domains as part of the same protein [17]. The reductase domain is similar to the mammalian P450 reductase 
[17]. Unfortunately, the BM3 enzyme is a fatty acid hydroxylase, and binds poorly to aromatic oxygen atom 
donors that have been used to generate Cpd I-like intermediates in the other bacterial isoforms. Recent studies 
by Jung et al., involving freeze-quench EPR analysis of intermediates of cytochrome P450BM3 generated using 
peracetic acid, suggested the formation of protein radical intermediates similar to those observed in P450CAM; 
however, no Cpd I was observed in these studies [14]. A mutant form of P450BM3, BM3–F87G, has recently 
been shown to favorably bind certain aromatic substrates, and was used in a previous stopped- flow 
investigation of the reaction of P450 with aromatic aldehydes and hydrogen peroxide [18,19]. Those studies 
showed that adducts to the heme resulted from the reactions. The mutant enzyme has a larger, more 
accommodating active site pocket that is well suited for binding relatively small aromatic oxene donor 
molecules such as mCPBA or iodosobenzene. 
 
In the current study, we have examined the reaction of substrate-free ferric cytochrome P450BM3–F87G with 
several different oxygen atom donors, including mCPBA, per- acetic acid, sodium m-periodate, and 
iodosobenzene, using stopped-flow spectrophotometric and freeze-quench EPR techniques, to directly observe 
intermediates that may play a role in the P450 catalytic function. 
 
2. EXPERIMENTAL 
 
2.1. Materials 
Cytochrome P450BM3 and the F87G mutant were produced in a recombinant bacterial expression system 
reported previously [18]. All reagents used in the experiments were purchased from Sigma, Aldrich, or Fisher 
Chemical suppliers. The reagents, mCPBA, peracetic acid, and sodium periodate, were purchased from Fisher. 
mCPBA was obtained as 70% pure reagent. Iodosobenzene (IOB) was purchased from TCI America chemical 
Corp. 
 
2.2. Stopped-flow experiments 
Experiments were carried out using either a Hi-Tech SF61DX double mixing stopped-flow system with diode 
array detection or an Applied Photophysics MVSX-18 single mixing system with diode array detector. The 
experiments involving P450BM3–F87G with the oxygen atom donors mCPBA, peracetic acid, or iodosobenzene 
were performed by mixing P450 with oxidant (30–500 µM) in 100 mM phosphate buffer at the specified pH. 
Temperature was controlled using a water bath connected to the stopped-flow system. Due to the instability of 
mCPBA in aqueous solution, a stock solution in ethanol was prepared and stored on ice, and fresh aqueous 
mCPBA solutions were prepared every 15 min. Reactions carried out using sodium m-periodate were 
performed in the same way, except a 40 mM aqueous stock solution of the salt was prepared and used over the 
course of the day. 
 
2.3. HPLC analysis of heme 
Procedures for extracting and analyzing the heme cofactor from BM3–F87G are described elsewhere in the 
literature [18]. 
 
2.4. EPR analysis 
All samples for EPR analysis were prepared by combining enzyme samples with the specified oxidant at 12 °C 
in an EPR tube and quenching the reaction by immersion in liquid nitrogen. Reaction times between 5 and 100 s 
were used in generating EPR samples with a final enzyme concentration of 165 µM in 100 mM phosphate 
buffer. The concentrations of mCPBA and iodosobenzene were between 0.50 and 2.0 mM. EPR spectra were 
recorded on a Bruker Instruments EMX 6/1 EPR spectrometer with microwave power between 0.005 and 20 
mW, using a frequency of 9.48 GHz and a modulation amplitude of 5 gauss. Spectra were recorded at 15 K and 
the temperature was controlled with an Oxford Instruments ESR 900 liquid helium cryostat. Sixteen scans of 42 
s each were summed for each spectrum. 
 
3. RESULTS 
 
3.1. Stopped-flow studies of the reaction of cytochrome P450BM3–F87G with mCPBA 
Addition of mCPBA (100 µM after mixing) to substrate- free ferric cytochrome P450BM3–F87G at pH 7.4 
(~20:1 ratio) resulted in the rapid appearance of a shoulder in the absorption spectrum at 370 nm and a decrease 
in the intensity of the Soret absorption peak with a slight red shift to 422 nm (Fig. 1). These spectral 
characteristics are indicative of the Cpd I shown previously [6–8]. Under these conditions, an additional 
intermediate with a λmax of ~406 nm was formed in a subsequent phase of the reaction (not shown). However, 
the excess of mCPBA used in this reaction resulted in rapid bleaching of the heme, so that full spectral 
characterization of this second intermediate was not possible. When only a ~6-fold excess of oxidant was used, 
the 370 nm shoulder, although present, was much less prominent, while the 406 nm absorbing species (B in Fig. 
2a) was much more stable and ultimately decayed back to a species resembling the ferric form of BM3–F87G 
over the course of 5 min, with less bleaching (C in Fig. 2a) than seen with ~20:1 mCPBA:P450. The 406 nm 
species is spec- 
 
trally very similar to Cpd ES shown with P450CAM [8]. Representative kinetic traces taken at 370, 406 and 418 
nm are shown in Fig. 2b and c. Rate constants for the different phases of this reaction were measured at 370 nm 
for phase 1, 406 nm for phase 2, and 418 nm for phase 3 as a function of mCPBA concentration. The average 
measured rate constants for each phase are reported in Table 1. As indicated by these data, only the initial phase 
of the reaction showed a significant dependence on the concentration of the oxidant used. The rate of 
conversion of the 370 nm absorbing intermediate to the one absorbing at 406 nm at pH 7.4 was nearly 
independent of the concentration of mCPBA, consistent with a sequential mechanism in which Cpd I initially 
formed converts to Cpd ES. 
 
At pH 6.8, addition of mCPBA to the ferric BM3–F87G enzyme resulted in a rapid decrease and slight red shift 
of the Soret absorption peak, followed by an increase at 406 nm, with little or no appearance of the shoulder at 
370 nm (Fig. 3). A clean isosbestic point at 412 nm observed after 10 ms was due to the conversion of the first 
intermediate to the species absorbing maximally at 406 nm. Along with the shift of the Soret peak to 406 nm, 
the absorption peaks at 535 and 568 nm decreased and a new feature at 623 nm appeared, as shown in Fig. 3. 
These results are consistent with formation of Cpd I followed by coversion to a Cpd ES-like species. The lower 
pH of 6.8 was more favorable for observing the Cpd ES-like species, similarly to the analogous reaction with 
P450CAM [8]. 
 
3.2. Double mixing stopped-flow analysis of the reaction between ferric P450BM3–F87G and mCPBA 
In a series of experiments involving double-mixing stopped-flow procedures, ferric BM3–F87G (8.0 µM final 
concentration) was initially combined with mCPBA (7:1) at pH 6.8 and aged for 5 s. Analysis of this reaction in 
the single mix mode revealed that formation of the 406 nm absorbing intermediate was maximal at 5 s. 
 
 
Following the 5 s aging time, NADPH (0.15 mM) was added in the second mix. At 15 °C, all of the 406 nm 
absorbing intermediate was converted back to ferric P450 within the mixing time (data not shown). 
Furthermore, excess NADPH was oxidized slowly by the resulting enzyme as indicated by loss of absorbance at 
340 nm. This result implies that formation of the species absorbing at 406 nm did not prevent the enzyme from 
accepting electrons from NADPH. It should also be noted that BM3– F87G oxidized NADPH even in the 
absence of a substrate, presumably via production of either H2O2 or H2O, indicating that initiation of the 
catalytic cycle did not require the presence of substrate. This type of uncoupling reaction in 
 
which a Cpd ES-like species becomes reduced back to the ferric heme with release of H2O2 or H2O, may also 
occur with microsomal cytochrome P450 enzymes for which BM3 is often used as a model. 
 
3.3. Reaction of P450BM3–F87G with other oxidants 
In addition to mCPBA, iodosobenzene, sodium m-periodate, and peracetic acid were each utilized as oxidants 
for substrate-free ferric P450BM3–F87G in stopped- flow experiments. In the reaction with iodosobenzene at pH 
6.8, a direct conversion of the resting ferric enzyme to the 406 nm absorbing species was observed with a clean 
isosbestic point at 412 nm (Fig. 4) that remained until bleaching began after about 10.0 s (data not shown). As 
with mCPBA, a new broad spectral feature was observed in the spectrum at 623 nm, with loss of the bands at 
535 and 568 nm. However, in contrast to the reaction with mCPBA, no shoulder at 370 nm was observed in the 
reaction at pH 7.4 with iodosobenzene; moreover, there was no red-shift in the Soret absorption peak prior to 
formation of the 406 nm peak, in contrast to that seen with mCPBA (Fig. 1). These results indicate that Cpd I 
does not accumulate in the reactions with iodosylbenzene, but that considerable Cpd ES-like species did. 
Presumably, the reaction with iodosobenzene to form the Cpd I was rate determining so that essentially no 
species with a shoulder at 370 nm accumulated before formation of the 406 nm absorbing species. Over a 5 min 
period, the 406 nm absorbing intermediate disappeared as the heme was slowly bleached. 
 
 
Reaction of ferric BM3–F87G with sodium m-periodate at pH 6.8 also resulted in the formation of the 406 nm 
absorbing intermediate, again with an isosbestic point at 412 nm, and, as with iodosobenzene, no Cpd I-like 
species with a shoulder at 370 nm could be observed under any conditions. Interestingly, in this reaction the 
Soret absorption peak decreased slightly over the first 100 ms and over the next 50 ms returned to its original 
absorbance (Fig. 5a). Over the same time period, the region of the spectrum between 350 and 400 nm steadily 
increased in absorbance. We do not know the chemical nature of this initial reaction. Starting at 0.15 s and 
continuing for 10 s, a monophasic shift of the Soret peak from 418 to 406 nm was observed (Fig. 5b), again 
consistent with formation of a Cpd ES-like species. This figure also shows the new broad peak at 625 nm 
associated with this intermediate, analogous to that seen with the other oxidants. 
 
Finally, peracetic acid was rapidly mixed with ferric BM3–F87G at pH 6.8 (Fig. 6) and at 7.4 (data not shown); 
only the 406 nm absorbing intermediate could be detected, even at concentrations in excess of 20 mM peracetic 
acid. As with the other oxidants, the appearance of the 406 nm Soret absorption peak was accompanied by a 
decrease in the 535 and 568 nm bands, and formation of a new broader 
 
 
 
 
band at 623 nm. Kinetic analysis of the data revealed a lag phase during the first 100 ms, with only a slight 
decrease in absorbance at 418 nm. This lag phase was followed by a direct conversion to the 406 nm absorbing 
intermediate. 
 
3.4. Electron paramagnetic resonance analysis of intermediates in the reaction of P450BM3–F98G with 
oxidants 
The reactions of ferric BM3–F87G with either mCPBA or iodosobenzene at pH 6.8 were carried out for 1–5 s, 
after which the reaction mixtures were rapidly frozen by immersing the EPR tubes into liquid nitrogen. The 
estimated time for freezing the sample was 4 ± 2 s. Spectra of mixtures with various P450:mCPBA ratios were 
recorded at 10 K. Increasing the concentration of mCPBA resulted in a more prominent signal at g = 2, with a 
decrease in the low-spin ferric heme signal with spectral components at g = 2.41, 2.25, and 1.92. The region 
around g = 2 was analyzed at microwave powers ranging from 5 µW to 20 mW for reactions with both mCPBA 
and with iodosobenzene. The spectrum obtained from the reaction with mCPBA appeared to show two different 
radical species, one at g = 2.005 with an isotropic line shape, and the other a multiple-lined signal represented 
by distinct components at g = 2.006, 2.017, and 2.026 (Fig. 7). The microwave power saturation behavior of the 
two signals differed noticeably, with the features at g = 2.006, 2.017, and g = 2.026 more easily saturated. The 
spectrum obtained from the reaction with iodosobenzene showed similar signals, but they were much more 
easily distinguished by varying the microwave power. The signal at g = 2.005 was very difficult to saturate at 
high powers, while the multiple lined signal was the dominant feature at low power. At 5 µW power, the latter 
signal comprised three features (g = 2.026, 2.017, 2.006) separated by 14–14.5 gauss, suggestive of an amino 
acid radical. Additional preliminary EPR data were acquired using 165 µM BM3–F87G and 1.7 mM mCPBA. 
With this high mCPBA:P450 ratio, a broad low intensity feature in the EPR spectrum at g = 1.78 emerged along 
with a sharp g ~ 2 peak, and the ferric P450 signals at g = 2.41, 2.25 and 1.92 were weak (data not shown). 
 
3.5. Analysis of heme products following reaction with oxidants 
Studies by Kuo et al. showed that the reaction of mammalian ferric P4502B4 from rabbit liver with mCPBA 
resulted in the formation of a covalently labeled adduct of the heme cofactor [20]. In order to ensure that such 
an adduct was not forming with the BM3–F87G enzyme, HPLC was performed on the heme cofactors. 
Following the reaction with each of the oxidants, samples of BM3– F87G were treated with isobutanone to 
extract the heme. The extract was dried under vacuum and the resulting residue was subjected to HPLC analysis 
to determine whether the heme had been modified during the reactions. HPLC analysis showed that the 
retention times and visible absorption spectra for hemes from each of the treated samples were identical to those 
of the native cofactor, indicating that no adducts analogous to those seen with P4502B4 formed. 
 
4. DISCUSSION 
 
Substrate-free ferric cytochrome P450BM3–F87G reacted with mCPBA to form several different spectral 
intermediates over the course of 1 s. The initial intermediate formed at pH 7.4 had characteristics similar to 
those of Cpd I from both P450CAM and CYP119 [6–8]. This Cpd I-like species converted partially to a Cpd ES-
like species, with a λmax of 406 nm, but a large fraction of the heme was also bleached via secondary reactions 
with the mCPBA. At pH 6.8, the species with a λmax of 406 nm was the predominant intermediate formed. Only 
a small amount of the Cpd I-like species could be detected by a very rapid increase at 370 nm (Fig. 2c). The 
Cpd ES-like species persisted for about 2 s before converting back mainly to ferric P450. Furthermore, at pH 
7.4, the rate of formation of the Cpd I-like intermediate was dependent on the concentration of mCPBA used, 
whereas the rate of conversion of this intermediate to the species absorbing at 406 nm was independent of 
mCPBA concentration. This observation suggests that the intermediate at 406 nm results directly from the 
decomposition of the Cpd I-like intermediate. Spolitak et al. recently showed similar behavior with substrate-
free ferric cytochrome P450CAM using mCPBA as an oxidant, and also demonstrated that peracetic acid could 
generate this intermediate that absorbed at ~406 nm [8]. They have tentatively assigned this species as a CcP 
Cpd ES-like intermediate in which a protein radical is formed by electron transfer to Cpd I. Freeze-Quench EPR 
and ENDOR experiments using wild-type and mutant forms of P450CAM suggested that the position of the 
protein radical was either Tyr96 or Tyr75, because mutation of both residues completely eliminated the Tyr 
EPR radical signal, whereas the single mutation at Tyr96 did not [11]. In contrast to P450CAM, P450BM3 has a 
Trp residue directly adjacent to the heme in the active site, as shown in Fig. 8 [21]. In fact, the environment 
surrounding Trp96 in BM3 is very similar to that of Trp 191 in CcP [22]. A propionate group from the heme 
cofactor in BM3 is within hydrogen bonding distance from the indole nitrogen of Trp (Fig. 8). The negative 
charge on the carboxylate can be expected to stabilize a 
 
 
 
positive charge on a Trp radical cation in Cpd ES, and this is consistent with the observation that the Cpd ES-
like species was clearly more stable in P450BM3–F87G than in P450CAM. A similar arrangement of a side chain 
carboxylate is believed to be involved in stabilization of the Trp radical in CcP where Cpd ES is quite stable 
[13]. 
 
The fact that P450BM3 is a fusion protein containing both a heme domain and a flavoprotein domain, allowed us 
to introduce electrons specifically to the active site of the protein via the physiological electron donor to BM3, 
NADPH. Thus, using a double mixing stopped-flow protocol, we showed that addition of NADPH to the 406 
nm absorbing intermediate resulted in rapid conversion of this species into ferric P450 with the FAD and FMN 
becoming reduced. Excess NADPH was oxidized slowly in this experiment as indicated by the loss of 
absorbance at 340 nm. These experiments showed that the intermediate species in question was clearly an 
oxidized form of the BM3 that could be rapidly reduced to give the ferric state of the enzyme in a peroxidase-
like reaction. Furthermore, the resulting enzyme, following oxidation to this species and reduction back to the 
ferric form, did not appear to lose its ability to oxidize NADPH. This implies that although substrate was not 
present, some of the heme can be reduced in a rate-limiting step, as indicated by the predominant species 
observed being the ferric heme. 
 
Prior studies with P450CAM showed that two different peracids (mCPBA and peracetic acid) were each effective 
in forming the Cpd ES-like intermediate; however, it has not previously been demonstrated that other oxidants 
have this capability. In the current study, we have shown that iodosobenzene also gives rise to this Cpd ES-like 
species, but without detectable formation of Cpd I. This is the case at both pH 6.8 and pH 7.4, in contrast to 
mCPBA, which leads to observable Cpd I formation at pH 7.4. The reaction of iodosobenzene with mammalian 
P450 isoforms was examined previously by stopped-flow techniques; however, the Cpd ES-like intermediate 
described in the current work was not detected [10]. We find that the inorganic salt, sodium m-periodate, is also 
capable of generating the Cpd ES-like intermediate. Although previous reports have indicated sodium m-
periodate can support P450-catalyzed hydroxylation reactions, no direct evidence for formation of oxidized 
P450 intermediates has been reported using this oxidant [23]. In addition to the Cpd ES-like intermediate, a new 
spectral feature was observed with this oxidant that was absent using other oxidants. An increase in absorbance 
below 400 nm was observed within 0.15 s of mixing. Periodate salts are known to initiate tyrosine dimer 
formation in proteins, and these dimers are characterized by electronic absorbances between 300 and 350 nm 
[24]. Two tyrosine residues at the surface of the BM3 enzyme, Tyr278 and Tyr429, are located within 3.6 Å of 
one another, and represent a potential site for dimer formation. The concentration of periodate (10 mM final 
concentration) was much higher than any of the other oxidants used, which may explain why this feature was 
only observed with periodate. Overall, these results with other oxidants suggest that Cpd ES arises from Cpd I. 
However, the kinetics of formation of Cpd I with the iodosylbenzene and with periodate were rate determining 
so that no Cpd I accumulated. We can suggest that the hydroxylation reactions brought about by using these 
latter two oxidants with P450 are thereby likely to occur via the nascent Cpd I. 
 
To further characterize the intermediates formed with BM3, we performed EPR analysis on samples that had 
been treated with mCPBA and rapidly frozen in liquid nitrogen after about 7 s. The stopped-flow data suggested 
that the ES-like intermediate in BM3 was considerably more stable than it was in P450CAM. This might be 
expected, given the potential stabilization of the putative Trp radical cation in BM3 via the heme propionate. As 
a result of the increased stability, the Cpd ES-like intermediate could be trapped without the need for a rapid- 
quench system. EPR spectra were recorded at different P450:mCPBA ratios. Increasing the relative amount of 
mCPBA resulted in a more prominent radical signal in the spectrum, with the disappearance of the low-spin 
ferric heme signal. The radical signal was examined in more detail at microwave powers ranging from 5 µW to 
20 mW. The saturation behavior of the radical signal and the observed hyperfine splitting at low power were 
consistent with the presence of a protein radical; however, different components of the EPR signal responded 
differently to changes in the microwave power, indicating the likely presence of multiple radical species. This 
became more apparent when iodosobenzene was used as an oxidant and the EPR spectrum was recorded. The 
three signals observed in the mCPBA reaction were all present, but their relative abundance was very different. 
The main species present in the iodosobenzene reaction was characterized by a multi- component EPR signal 
with g-values of 2.026, 2.017 and 2.006. Although these peaks were also present in the mCPBA reaction, they 
were minor compared to the main peak at g = 2.005. While we are unable to assign the observed radical to a 
specific amino acid residue in this intermediate, the behavior of the radical signal is consistent with either a Tyr 
or a Trp, or possibly a combination of both [25]. 
 
A possible explanation for this is that the two radical species originate on different amino acid side chains, and 
that the two oxidants react differentially with these residues. Assuming that at least one of the two surface 
tyrosine residues discussed earlier may be oxidized, this is certainly feasible. Alternatively, it is possible that the 
two oxidants produce different ratios of the intermediates represented in Scheme 1. For example, the g = 2.005 
signal that dominates the mCPBA reaction may represent a small amount of Cpd I (porphyrin n-cation radical), 
whereas the multi-component signal dominating the iodosobenzene spectrum would represent a protein radical, 
possibly Trp-96. Rutter et al. reported the 9.5 GHz EPR spectrum for compound I of chloroperoxidase (CPO) 
under several different conditions, and in each case the signal consisted of g ~ 2 and g = 1.73 components 
[26,27]. As with CPO, the preliminary EPR spectrum of P450BM3–F87G, when mixed with mCPBA for ~1 s, 
using a 10:1 mCPBA:BM3 ratio, contained a sharp g ~ 2 component and a broad weak signal at g = 1.78 (data 
not shown). The experiment with BM3 was carried out at 10 K using 20 mW power, in contrast to the CPO 
experiment, where the microwave power was between 50 µW and 1 mW, and the temperature was between 3.6 
and 30 K. Although the similarity of the CPO and BM3–F87G EPR spectra alone does not prove that Cpd I is 
present in the P450 experiments, the combination of the EPR and the stopped-flow data (discussed above), 
argue more strongly that a compound I-like intermediate and a compound ES-like intermediate both are 
produced using mCPBA as an oxidant, whereas with iodosobenzene, the Cpd ES-like intermediate accumulates 
almost exclusively. 
 
The fact that this ES-like species can undergo rapid reduction by NADPH suggests that formation of Cpd ES 
may provide a viable protective or uncoupling mechanism for this enzyme. For example, when the enzyme 
reacts with NADPH and oxygen in the absence of substrate or in the presence of a non-optimal substrate, Cpd I 
is produced (a very reactive species). Instead of heme destruction, Cpd I converts to Cpd ES, which is less 
reactive than Cpd I. Subsequently, two additional electrons from NADPH pass through the reductase domain to 
reduce Cpd ES to the ferric state. The only products formed are water and NADP
+
, rather than reactive oxygen 
species. This proposed sequence of events is outlined in Scheme 1. From the EPR and stopped-flow studies, we 
conclude that a Cpd ES-like complex in cytochrome P450BM3 results from the oxidation of an active site 
aromatic amino acid by Cpd I formed in the reaction of this P450 isoform with alternate oxygen atom donors. 
The relevance of this intermediate to the catalytic function of this or certain microsomal enzymes remains to be 
determined. 
 
In summary, the stopped-flow data presented herein provide the first direct observation of a Cpd-I-like 
intermediate in a class-II or III cytochrome P450 enzyme, BM3– F87G. Preliminary EPR data have also been 
obtained that are consistent with this interpretation that is based on analogous studies with chloroperoxidase 
[26,27]. Finally, a compound ES-like intermediate has been observed using not only peracid-type oxygen atom 
donors, but also iodosobenzene and sodium m-periodate. Cpd ES in BM3–F87G was shown to be easily 
reduced to the ferric state by NADPH. A protective biological role for P450 Cpd ES in avoiding the production 
of reactive oxygen species from P450 Cpd I is proposed. Similar results have been seen in parallel studies of 
cytochrome P450CAM [28]. 
 
5. ABBREVIATIONS 
 
mCPBA m-Chloroperoxybenzoic acid 
Cpd I  compound I 
Cpd ES compound ES 
CcP  cytochrome c peroxidase 
BM3–F87G cytochrome P450BM3–F87G, BM3;  
cytochrome P450BM3 
EPR  electron paramagnetic resonance 
ENDOR electron nuclear double resonance 
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